Journal

GLP-1s After 65: The Risks That Differ From Younger Patients

Muscle loss, malnutrition and bone density concerns are materially different in older adults, and Medicare has just opened access.

Why age changes the calculation

Three differences compound. Older adults typically have less lean mass to begin with, so a given percentage loss costs more functionally. Age-related bone density decline means additional loss lands on a lower baseline. And appetite suppression in someone already eating less can shade into inadequate intake more quickly.

None of these makes GLP-1 therapy inappropriate in older adults — obesity in this group carries its own serious risks, and the SUMMIT trial found benefit specifically in obesity-related heart failure with preserved ejection fraction. They make it a treatment that needs monitoring rather than a prescription that needs filling.

What the 2026 reviews are recommending

Clinical commentary through 2026 has converged on several practices for older patients. These belong to a prescriber who knows your history; they are described here so you know what a thorough programme looks like.

• Baseline body composition and bone density assessment before starting, so change can be measured rather than assumed.
• Attention to protein intake, at levels above general adult guidance.
• Resistance training as a companion to therapy, not an optional extra.
• Slower dose escalation than standard protocols, to moderate the rate of weight loss.

That last point aligns with the label rather than departing from it. The Zepbound label directs increases in 2.5 mg increments no sooner than every four weeks, based on tolerability and response. It sets a minimum interval, not a schedule — and there is nothing in it requiring anyone to reach 15 mg.

The access change that makes this urgent

The Medicare GLP-1 Bridge began 1 July 2026, giving eligible Part D enrollees certain GLP-1s at a flat $50 monthly copay through 31 December 2027. Federal law otherwise excludes weight-loss drugs from Part D.

That is a large, sudden expansion of access in precisely the population where the monitoring questions are hardest. The programme covers the medication; it does not itself provide the baseline scan, the dietetic input or the resistance training that the clinical literature keeps pointing to.

Questions worth asking before starting after 65

1. What will you measure before I start, and what will you re-measure?
2. Given my other medications, what interactions matter?
3. How fast do you plan to escalate, and what would make you slow down?
4. What are the signs that I am losing weight too quickly or eating too little?
5. What is the plan for maintaining muscle, and who helps me with it?
6. Who do I contact between appointments, and how fast do they respond?

A prescriber who answers all six is treating this as a clinical process. A platform that cannot answer them is selling a subscription.

What we do not know

Long-term functional outcomes in older adults on these drugs are not well characterised. Fracture risk over years has not been established. And whether slower escalation actually preserves function — as opposed to composition — has not been tested in a trial.

Questions readers actually ask